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Abstract
The therapeutic focus of the scientific community in Alzheimer’s disease (AD) has been moving in the last years from attempting 
late rescue against cholinergic degeneration and amyloid beta plaque clearance to (i) the discovery of blood or cerebrospinal 
fluid markers for early diagnosis, and (ii) early therapeutic intervention with modulators of amyloid precursor protein (APP) 
processing. It is currently accepted idea that subtle synaptic alterations determine the first neuronal dysfunctions and cognitive 
deterioration, progressing overtime into neuronal degeneration in the sporadic and late onset form AD (LOAD), the most diffuse 
one (90% of AD cases). synaptic loss occurs long before the appearance of a frank neuronal degeneration in LOAD. The pertur-
bation of the nerve growth factor (NGF) signalling system in brain neurodegenerative disease like AD and Down’s syndrome 
was for long time considered to be a pathological event, subsequent to amyloid-driven disruption of NGF retrograde transport 
from the cortex and hippocampus to the cell bodies of basal forebrain cholinergic neurons. Nowadays, an increasing amount of 
data indicate that the observed dysregulation of NGF-TrkA (tyrosine kinase A) and proNGF-p75NTR signalling systems is a good 
candidate for being the primus movens in the neuropathology of sporadic AD. Accordingly, an amyloid-independent strong 
correlation of cognitive deficits with reduction of NGF and TrkA, and accumulation of proNGF has been recently observed in 
mild cognitive impairment and its progression to AD. This review highlights the current knowledge about NGF and early events 
occurring in LOAD. The involvement of muscarinic acetylcholine receptors, cholesterol, sirtuin1, insulin-like growth factor-1, 
and sunday driver protein in APP processing are also discussed. The studies reported here confirm a multitasking ability of NGF 
in slowing down, through both distinct and overlapping mechanisms, the amyloidogenic processing of APP in neurons of the 
central nervous system.
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introduction
Alzheimer’s disease (AD), the most common cause of dementia 
in the elderly, is a progressive neurodegenerative disorder 
characterized by impaired memory and cognit ion.  There are 
two forms of AD: (i) the genetic early onset familiar AD (FAD), 
with mutations in the amyloid precursor protein (APP) prese-
nilin (PS1 and PS2) genes, and (ii) the age-related, sporadic and 
late onset AD (LOAD), representing 90 % of AD cases (1). FAD 
and LOAD are characterized by increased levels of APP, and the 
presence of neuritic amyloid plaques, cerebrovascular amyloi-
dosis and neurofibrillary tangles. 
APP is a transmembrane protein, and its expression is ubiq-
uitous (2), although neuronal tissues express a tissue-specific 
isoform, the APP695 (human APP numbering) (3). APP is 
thought to be a pathogenic factor in AD, as a result of the pro-
teolytic processing of the protein, and the generation of neuro-
toxic carboxyl-terminal (C-terminal) derived peptides (4). APP 
cleavage occur at the membrane by beta secretase 1 (BACE1), 
or by a disintegrin and metalloproteinase 10 and 17 (ADAM10, 
ADAM17), the neuronal alpha secretases. As a result the shed-
ding of the large APP ectodomain occurs and the extracellular 
soluble APP derivatives are released (sAPPbeta and sAPPalpha, 
respectively), and membrane-tethered C-terminal fragments 
(CTFs) are generated (CTFbeta or CTFalpha, respectively). The 
CTFs are subsequently cleaved by gamma-secretase to generate 
either amyloid beta (Abeta) and the APP intracellular domain 
(AICD) (from APP-CTFbeta), or a 3 kD product (p3, from APP-
CTFalpha). CTFbeta derived fragments (Abeta and AICD) and 
the CTFbeta itself are considered to be the toxic species in AD 
(5). 
Despite recent progress in AD research, the  t reatment  of 
AD remains  a  major challenge. The knowledge of the trig-
gering events leading to the selective degeneration of basal 
forebrain cholinergic neurons (BFCN), a characteristic of AD 
brains, is far to be exhaustive. 
Neurotrophic factors have attracted the attention for neu-
roprotection in neurological disorders (6,7). In this re-
gard, nerve growth factor (NGF) has generated a great 
interest as a potential target for the treatment of AD (8-
11). This is based on the observation of the concomitant 
degeneration of BFCN, reduced availability of NGF and its 
high-affinity receptor, the tyrosine kinase A (TrkA), and in-
creased APP levels in the AD post mortem forebrain. 
Increased APP levels have been found also in other age re-
lated and neurodegenerative pathology of the central nervous 
system (CNS), like Down’s syndrome (DS) (12) and traumatic 
brain injury (TBI) (13,14). DS patients present a disrupted NGF 
trafficking and develop a form of dementia similar to AD (15). 
An age-related decrease of NGF-like immunoreactivity and a 
parallel increase of APP (16) have been reported also in the ba-
sal forebrain of senescence-accelerated mice 10 (SAMP 10), a 
valuable mouse model for brain ageing (17).
Numerous evidences from both animal and human stud-
ies indicate NGF may be useful in reversing, stopping, or at-
tenuating the cognitive deficit associated with AD, DS and TBI 
(10,12,18-20). A phase I clinical trial based on ex vivo NGF gene 
delivery by implantation of fibroblast engineered to express hu-
man NGF in the forebrain of AD patients showed no long-term 
adverse effects and a promising degree of efficacy as evaluated by 
Mini-Mental Status Examination (MMSE), PET scan and brain 
autopsies (21). This study didn’t include a placebo control group, 
thus warranting additional analyses. A Phase II clinical study of 
Ceregene’s CERE-110, a gene therapy product designed to se-
lectively deliver NGF to the Nucleus Basalis of Meynert for the 
treatment of early and mean phase AD, is currently underway by 
the Alzheimer’s Disease Cooperative Study (ADCS; http://www.
adcs.org).
Since AD is a pathology of BFCN and NGF is a tropic and 
trophic factor for BFCN, it has been hypothesized that NGF 
might exert neuroprotective effects in AD. However, it is also 
possible that the AD cognitive deficits are acetylcholine inde-
pendent and that the effect of NGF does not simply rely on res-
toration of cholinergic neurotransmission and BFCN survival. 
A recent study (22) demonstrated that not all the BFCN strictly 
depend on NGF-TrkA for their differentiation and/or survival. 
In this study, transgenic mice with ngf or trkA conditional gene 
ablation in the CNS showed a developmental reduction of only 
35-40% of BFCN expressing choline acetyltransferase enyzme 
(ChAT). Moreover, young and middle aged mice showed nor-
mal behaviour in a number of septo-hippocampal, cortical and 
para-hippocampal tasks (22), questioning about relevance of 
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NGF-dependent BFCN for AD-targeted cognition. The ongoing 
analysis on aged NGF and TrkA CNS knockout (KO) mice will 
allow a better understanding of NGF and cholinergic depend-
ency of cognitive functions in the healthy and AD forebrain. An 
increasing amount of data let us speculate that NGF relevance 
in AD involves early brain changes other than the well-known 
cholinergic dysfunction in AD. Studies on cholinergic NGF and 
TrkA expressions in MCI and in AD brain indicated that the 
early NGF-TrkA system alteration correlate with cognitive defi-
cits and occurs before the appearance of any cholinergic damage 
(23,24). Though it is not definitively assessed whether the NGF 
deficits is a primary perturbation  in AD or a secondary effect 
of the Abeta disrupted axonal transport, recent evidences offer a 
new perspective on NGF in AD pathogenesis. 
The present review updates the current knowledge of cellular 
and molecular mechanisms of NGF-modulated APP processing, 
underlying its anti-amyloidogenic effect in healthy, aged and 
AD brain: a central issue in the discovery of novel therapy for 
this devastating disease. 
Muscarinic acetylcholine receptors 1 (Mr1)  
and non-amyloidogenic APP processing
The activation of muscarinic acetylcholine receptor 1 (MR1) has 
been shown to stimulate non-amyloidogenic APP processing in 
cultured cells and brain slices (25, 26). Also the in vivo stimula-
tion of muscarinic tone on cholinergic targets of the BFCN by 
the administration of MR1 agonist resulted in increased sAPPal-
pha levels (27) and decreased Abeta levels in the cerebrospinal 
fluid (CSF) of AD patients (28,29). Conversely, MR1 inhibitors 
favour the amyloidogenic route in the Tg2576, transgenic AD 
mouse model (30). Studies with MR1-KO mice indicated that 
MR1 is sufficient to modulate alpha cleavage of APP and sAP-
Palpha release (31). Muscarinic tone is affected also in the AD11 
mouse model of AD, expressing neutralizing levels of anti-NGF 
antibody. The fact that the nicotine-dependent enhancement of 
synaptic efficacy failed at the CA1 synapses of AD11 (32) prob-
ably reflects an NGF-dependent deficit at the cholinergic targets 
rather than a lack of cholinergic neurotransmitters. Although 
further studies are needed to specifically address the role of NGF 
on MR1-dependent anti-amiloidogenic APP processing, the 
available data support the idea of NGF as anti-amyloidogenic 
neurotrophin of the basal forebrain.
the mature nGf versus pronGf signalling pathways  
in APP metabolism
Neurotrophins are synthesised as preproforms, subsequently 
cleaved by furin and procaspases to generate mature neurotro-
phins. The precursor and mature forms of the neurotrophines 
are thought to activate distinct and sometimes opposite effects 
on APP metabolism in the CNS (33).  For instance, the mature 
form of NGF (mNGF) signals through the specific receptor 
TrkA (34) and the panneurotrophic receptor p75NTR (35), to in-
duce MAPK/ERK survival pathways and neuronal differentia-
tion (36). The unprocessed proneurotrophin peptide (proNGF) 
has a minimal affinity for TrkA, beeing a preferential high-affin-
ity ligand for the p75NTR-sortilin signalling complex, and leading 
to JNK/SAPK activation and neuronal death (37,38). 
The proNGF-p75NTR-sortilin trimeric complex drives a pro-
apoptotic pathway and induces an age-dependent ceramide 
production, BACE activation, and beta fragments production 
in cultured hippocampal neurons (39). A prevailing proNGF 
signalling may further accelerate neuronal damage and wors-
en brain pathology in AD, because of its ability to downregu-
late mNGF-TrkA driven survival signals, as it has been shown 
in vitro, both in PC12 (40) and in brain neurons (41). In vivo, 
proNGF levels augment in AD tissues, where it localizes to the 
Abeta plaques (42). The accumulation of proNGF has been 
found to induce cholinergic degeneration following a pharma-
cologically induced failure in NGF maturation (43) and to cause 
learning and memory deficits in transgenic mice expressing a 
furin cleavage-resistant form of proNGF (proNGF trasgenic 
mice) (44). 
Epileptic activity is associated to AD, and AD carries a sig-
nificant increased risk of seizures, observed in 10-22% of LOAD 
patients. Interestingly, proNGF transgenic mice display sponta-
neous epileptic-like discharges (44), and epileptic seizures, on 
the other hand, triggers a significant increase in proNGF and 
p75NTR expression in hippocampal neurons (45,46). Although it 
is not clear whether AD and seizures are one the epiphenom-
enon of the other or two distinct diseases sharing some initial 
mechanisms, these data further indicate the proNGF-p75NTR 
system as a molecular substrate for the early events taking place 
in LOAD (46). 
A shift from mRNATrkA to mRNAp75NTR transcription occur-
ring as a result of brain ageing and insulin-like growth factor 
1 (IGF1) signalling, and leading to reduced TrkA and increase 
p75NTR-ceramide signalling pathways was first hypothesized by 
Puglielli (47,48). Of notice, the expression of IGF1 and the IGF 
receptor (IGF1R), classically associated to diabetes and meta-
bolic diseases, has been recently shown to modulate lifespan, 
age-related amyloidogenesis and LOAD-like pathology (49-51). 
These observations, claiming AD as a brain type diabetes, or 
“type 3 diabetes” (52), link the TrkA-to-p75NTR signalling switch 
with the IGF1-affected neuronal metabolism in brain aging and 
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age-related AD. In agreement with this, cognitive impairment is 
associated with decreased levels of TrkA and doubling of p75NTR 
levels in the brain of aged rats (53) and in early AD patients (54). 
Given the opposite functions of mNGF and proNGF in the 
mature brain, and the pro-amyloidogenic effect of a prevailing 
proNGF-p75NTR signalling in ageing and AD, novel proNGF-
based approaches could represent a very promising route for 
LOAD treatment. Experimental studies have been successfully 
attempted in order to minimize proNGF levels, p75NTR signal-
ling or rescue mNGF/proNGF ratio in several AD animal mod-
els. Among these, (i) the administration of mNGF (55), (ii) the 
selective inhibition of proNGF/p75 signalling (56), (iii) the use 
of cerebrolysin (CBL) in the Tg2576 AD mouse model and in 
AD patients (57), and (iv) the treatment  of APP/PS1 transgenic 
mice with the green tea derived compound epigallocatechin-
3-gallate (EGCG) (58).
Interestingly, a recent paper showed lack of correlation of 
Abeta with both the severity and progression of cognitive defi-
cits in MCI and early AD, while a strong correlation was found 
with increased proNGF, and decreased NGF and TrkA levels, 
leading to the hypothesis that an initial and amyloid independ-
ent perturbation of the neurotrophic signalling can occur in 
sporadic dementia (59). 
p75ntr signalling, nrif and the cholesterol connection
Numerous epidemiological studies suggest that cholesterol plays 
a significant role in the development of AD. Patients with AD, 
administered with cholesterol synthesis inhibitors, collectively 
termed statins, have reduced incidence of the disease (60). 
Indeed, the identification of a genetic variant of the apolipo-
protein E (APOE), a cholesterol transporter, as a major genetic 
risk factor for AD is also consistent with a role for cholesterol 
in the pathogenesis of AD (61). In the same vein, deficiency of 
ATP-binding cassette transporter A1 (ABCA1), which regulates 
cholesterol efflux, increased Abeta deposition in different AD 
models (62).
Furthermore, animal studies have shown that a high fat/high 
cholesterol diet exacerbated the signs of the disease in a trans-
genic mouse model of AD (63), while treatment with inhibitors 
of cholesterol synthesis was protective (64,65). These findings 
are supported by several biochemical data reporting that the 
APP processing is directly affected by cellular cholesterol con-
tent (66,67). 
Cholesterol, the main component of caveolae and lipid rafts, 
influences the activity of the enzymes involved in the metabo-
lism of the APP, by promoting beta and gamma cleavage of 
APP (68), and generating the toxic CTF beta and Abeta toxic 
species (69). Moreover, increased membrane cholesterol might 
render mature hippocampal neurons more susceptible to Abeta-
induced tau toxicity (70) and cause the memory impairments 
and cognitive decline characteristic of AD (71). Recent advances 
in the neurobiology of neurotrophins suggest p75NTR signalling 
as the one responsible for the increased cholesterol content in 
neurons. In fact, p75NTR regulates the expression of several cho-
lesterogenic enzymes in both Neuro2a cells and primary neu-
ronal cultures (72).
The mechanisms of the p75NTR-dependent regulation of cho-
lesterol synthesis seems to involve a 94 kD zinc finger protein 
of the Kruppel family, called neurotrophin receptor interacting 
factor (NRIF) (73), which may function as an intracellular inter-
actor of p75NTR, thus mediating ceramide and BACE1 increase as 
well as p53-dependent apoptosis in neuronal cells (74,75). NRIF 
has also been shown to be an essential activator of cholesterol 
biosynthetic genes. In fact, NRIF reduction resulted in reduced 
expression of sterol-sensing domain protein SCAP, followed 
by a decrease in mRNA levels of SRE-motif containing genes 
(HMGCR, FASN, SREBP2, S1P, and SQS1) in both in vitro and 
in vivo paradigms of NRIF depletion (73). The exact molecular 
events leading to p75NTR-NRIF driven cholesterol synthesis have 
not been described yet, while the mechanisms of the p75NTR-
NRIF mediated apoptosis have been well characterized. In the 
p75NTR-NRIF driven apoptotic cascade, the release of the p75 in-
tracellular domain (ICD) by ADAM-17 (76), through regulated 
intramembrane proteolysis (RIP), is necessary for NRIF poly-
ubiquitination by the E3 ligase TRAF6 (77), and subsequent nu-
clear translocation and target gene regulation (78).
The study of NRIF expression and cholesterol biosynthesis 
in vivo in animal models with unbalanced proNGF-p75NTR ver-
sus mNGF-TrkA signalling, like proNGF transgenic mice, and 
TrkA CNS-KO mice could give new highlights on the molecular 
events of cholesterol-dependent amyloidogenesis in adult CNS 
neurons. Further studies are needed to address the question of 
the potential involvement of the p75NTR-NRIF complex in the 
regulation of neuronal cholesterol homeostasis. However, the 
hypothesized p75NTR-NRIF-cholesterol cascade is likely to be 
very important for neuronal membrane homeostasis and synap-
tic function in brain ageing and AD (79). 
nGf and the longevity:  
the anti-amyloidogenic protein sirtuin1
Silent information regulator (sir) genes encode for epigenetic 
regulatory proteins, collectively designated sirtuins (SIRT). 
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SIRT1 is the best characterized enzyme of the sirtuin family of 
nicotinamide adenine dinucleotide NAD+-dependent protein 
deacetylases, which include 7 members (SIRT1-7). Sir2 protein 
found in the yeast is most likely one of the key proteins in medi-
ating the caloric restriction (CR)-dependent lifespan extension 
in yeast as well as in invertebrates (80). Because sir2 is conserved 
from prokaryotes to mammals, the human SIRT1 has gained 
considerable attention for its impact on mammalian physiology, 
and for defining novel therapeutic targets for treating diseases 
associated with aging, like AD, and in extending human lifespan.
Although most of the sirtuins, and SIRT1 in particular, are 
highly expressed in the brain (81), at present very little is known 
about their roles and targets in the nervous system. Most stud-
ies of SIRT1 in the mammalian brain have focused on its role in 
neuroprotection.  SIRT1 appears to inhibit axonal degeneration, 
a process that often precedes neuronal death in neurodegenera-
tive diseases (82). As for the APP metabolism, SIRT1 was found 
to protect neurons by downregulating the amyloidogenic Rho 
kinase (ROCK1) expression in neurons (83,84). In vivo, SIRT1 
was able to suppress Abeta production and cognitive decline in 
the p25 transgenic mice (85) and in the double APPswe/PS1dE9 
transgenic mice, by inducing ADAM10 expression (86).
As a confirmation of SIRT1 relevance to normal cognitive 
functions in the normal mammalian brain, SIRT1 has been 
shown to sustain brain metabolism (87), neurogenesis (88), as 
well as learning and memory in the adult brain (89). On the op-
posite, the decline in serum concentration of SIRT1 correlates 
with both tau pathology (90) and severity of cognitive deficits in 
patients with MCI and AD, as well as in aged healthy individu-
als (91). 
Together, these findings call for increased examination of 
SIRT1 and for novel potent SIRT1 activators as protective strat-
egy in neuronal ageing and AD-like neurodegeneration (80). 
Intriguingly, NGF is a potential SIRT1 activator in the mamma-
lian neurons in vitro and in vivo. NGF signalling through the 
cAMP responsive-element binding (CREB) has been shown to 
activate SIRT1 transcription in both pheochromocytoma cell 
line (PC12) and primary neurons (92).  Moreover, NGF has 
been shown to induce a well known SIRT1 substrate, the per-
oxisome proliferator-activated receptor gamma coactivator 1-al-
pha (PGC-1alpha), thus promoting mitochondrial biogenesis in 
PC12 and primary neurons (93). The decrease of PGC-1 alpha 
mRNA expression was found to significantly correlate with the 
progression of AD (94), and the reconstitution of exogenous 
PGC-1alpha expression in Tg2576 neurons attenuated ROCK1 
driven amyloidogenesis (94 90).
Overall, NGF could exert its anti-amyloidogenic effect 
through SIRT1-dependent increase of both ADAM10 transcrip-
tion on one side and of PGC1alpha (inhibiting ROCK1 mediat-
ed beta processing) on the other side: a valid rationale for thera-
peutic targeting of NGF and/or NGF downstream molecules in 
AD neurodegeneration.
nGf and APP metabolism: a direct link?
Several lines of evidence point to a direct regulatory effect of 
NGF on APP metabolism and processing. The  p75NTR (but not 
the TrkA) signalling is able to increase APP translation rates in 
PC12 cells (95), while TrkA signalling promotes the anti-amy-
loidogenic APP processing, favouring the release of sAPPalpha 
(96). Contrary, the interruption of NGF signalling by NGF with-
drawal leads to a strong increase in total APP levels and Abeta 
production in PC12 and primary neurons (97,98). Moreover, the 
stable expression of a neutralizing anti NGF antibody in AD11 
transgenic mice caused an age dependent increase in Abeta, 
leading to both short and long term plasticity defects in vivo 
(99-101). 
In the APP molecule, the APP C-terminal has a critical role 
for developmental functions of APP (102) and in regulating APP 
processing (103), possibly through the modulation of the APP 
interacting proteins binding its intracellular tail (104).  Several 
residues are involved (S675, Y682, T686, and Y687), but the 
most relevant in the adult brain functions are the tyrosine 682 
(Y682) in the Y682NPTY motif and the upstream threonine 668 
(T668, numbering of APP695) (104). The binding of interact-
ing proteins to APP depend on the pattern of APP phospho-
rylation at the cytosolic tail. Several APP interactors have been 
found to bind the Y682 when phosphorylated (shc, grb2/7, src) 
and others when not phosphorylated (Fe65, Numb, JIP1) (104). 
Phosphorylated Y682 (pY682) and, thus, the specific APP inter-
actors binding to pY682, have been associated with altered APP 
processing in vitro, in vivo and in AD (103,105). 
More than a decade ago D’Adamio found very high levels of 
tyrosine phosphorylated APP and TrkA in cells overexpressing 
constitutively active form of the Abl tyrosine kinase (106). He 
also demonstrated that (i) activated TrkA is necessary to achieve 
APP tyrosine phosphorylation, given that the dominant nega-
tive TrkA mutant form lacking the kinase domain is unable to 
phosphorylate APP, and (ii) TrkA overexpression modulate APP 
processing decreasing the amount of AICD produced (107). 
Furthermore, TrkA is capable not only of modulating the phos-
phorylation pattern of APP, but it also directly binds to APP 
when phosphorylated at Y682. The lack of the Y682 docking 
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site, in mice bearing a tyrosine to glycine point mutation (APPYG 
mice), abolishes APP interaction with TrkA, affects their cellu-
lar distribution (108), and impairs TrkA signalling, cholinergic 
functions and cognition (109). 
As described above, the APP C-terminal can be also phospho-
rylated at the threonine residue T668, upstream the Y682NPTY 
motif (APPpT668). T668 phosphorylation is likely to be involved 
in the intracellular sorting and trafficking of APP, which in 
turn impacts on the APP amyloidogenic cleavage (110). In fact, 
APPpT688 levels are known to (i) be elevated in dystrophic neu-
ritis and amyloid plaques of AD brain (110), (ii) favour APP/
BACE interaction and the consequent beta cleavage of APP 
(110), and (iii) lead to Abeta and tau accumulation in AD and 
in Tg2576 mice (111).  Notably, IGF1 has been shown to modu-
late APP processing by reducing the levels of APPpT668 in human 
neuronal cell lines (112). Since T668 is the best characterized 
residue of the APP cytosolic tail, strongly implicated in amy-
loidogenic processing, production of the toxic beta CTFs and 
neuronal degeneration in AD, the potential role of NGF in the 
described events could be of great therapeutic interest for AD 
and age-related neurodegeneration. 
Taken together, the effect of NGF-TrkA on Y682 phosphoryla-
tion and APP processing indicate a very tight connection between 
NGF-TrkA signalling system and APP molecule and suggest a 
complex scenario bridging the NGF-driven pattern of APP phos-
phorylation with a phospho-driven specific APP interactome of 
great potential interest for neurodegeneration in the CNS. 
nGf, APP and the sunday driver protein:  
stuck along the axon
The endocytic internalization of the ligand-receptor complex 
and the axonal trafficking of neurotrophin receptors suffer per-
turbations in a number of neurodegenerative diseases, including 
the NGF-TrkA system retrograde transport in the BFCN affected 
by AD. In particular, NGF requires an intact axonal cytoskeleton 
to transduce its signalling potentials (113). Coherently, NGF re-
ceptor TrkA has been found to interact with a key cytoskeleton 
protein, the sunday driver (SYD) protein (114). SYD2, a recently 
characterized member of the SYD family, is another name for 
the c-jun kinase (JNK) interacting protein 3 (JIP3). SYD2-JIP3 
is a neuronal-enriched scaffolding protein for JNK: it binds both 
to JNK3 and APP, favouring APP phosphorylation, leading to 
amyloidogenesis, and activating the apoptotic cascade. Thus, 
SYD2/JIP3 protein can be speculated to be the missing link be-
tween perturbations of cytoskeletal trafficking of key neurotro-
phin receptor, like TrkA, amyloidogenic APP phosphorylation 
and the JNK dependent apoptotic signalling cascade (114). It is 
unknown whether the impaired NGF-TrkA signalling cascade 
or the cystoskeletal machinery defects come first in AD neuro-
degeneration.  The possibility that an initial neurotrophic unbal-
ance may in turn affect APP/SYD2-JIP3 transport and signal-
ling, thus mediating apoptosis via a switch from the (inhibited) 
RAS/MAPK-PI3K-signaling toward the (activated) SYD2-JIP3/ 
JNK3/p38MAPK amyloidogenic-apoptotic pathway cannot be 
excluded and deserves further studies. 
The deeper understanding of the NGF signalling defects and 
cytoskeleton dysfunction in AD will hopefully allow more tar-
geted and effective interference with amyloidogenic-apoptotic 
events occurring in MCI and early AD (115,116).
Conclusion
Though brain ageing is universally considered to be a major 
risk factor for developing LOAD, nowadays there is a lack of 
knowledge on molecular pathway(s) responsible for the shift-
ing from normal brain aging toward AD neurodegeneration. On 
the other hand, normal ageing doesn’t necessarily evolve into 
AD. Genetic abnormalities, environmental factors (exposome), 
physical illnesses, and cardiometabolic diseases (50-52,117,118) 
and/or a combination of them could act as a second ”hit”, break-
ing brain homeostatic responses and leading to progressive neu-
ronal damage and final cell loss.
The evidences herein reported prompt the idea of NGF exert-
ing pleiotrophic actions through multiple substrates and path-
ways and down-regulating the amyloidogenic APP processing 
(Fig. 1), thus opening a new perspective in the understanding 
of neuronal pathology in age-related LOAD. After decades of 
scientific hypotheses centered on acetylcholine, Abeta and tau, 
today we may re-think to the significance of NGF alterations 
in AD and consider the age-driven perturbation of NGF-TrkA 
and proNGF-p75NTR signalling systems in the CNS neurons as a 
promising first “hit” in LOAD. 
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Figure 1. A schematic representation of the anti-amyloidogenic mNGF-TrkA versus the amyloidogenic proNGF-p75NTR singalling 
pathways. A prevalent TrkA, and ERK/MAPK activation sustain normal metabolism and synaptic plasticity, while the increase of 
p75NTR and JNK/sAPK signalling pathways induced by age/stress lead to neurodegeneration and apoptosis in neurons of the 
central nervous system.  
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